Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Visser, Jantien ^a   Snel, M ^b   Van Haam, Vliet ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ESTROGEN; GESTAGEN; GESTODENE; GLYCOSYLATED HEMOGLOBIN; LEVONORGESTREL; LYNESTRENOL; NORETHISTERONE; NORETYNODREL; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DATA ANALYSIS; DEMOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INFORMATION PROCESSING; INSULIN DEPENDENT DIABETES MELLITUS; INTERVENTION STUDY; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVENTION AND CONTROL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 42749104224     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003990.pub3     Document Type: Review

References (43)

1. Radberg T, Gustafson A, Karlsson K, Skryten A. Oral contraception in diabetic women. Diabetes control, serum and high density lipoprotein lipids during low-dose progestogen, combined oestrogen/progestogen and non-hormonal contraception [Hormonell och ickehormonell contraception i relation till diabeteskontroll och lipidmetabolism]. Acta Societatis Medicorum Suecanae 1979;88:212.
2. * Radberg T, Gustafson A, Skryten A, Karlsson K. Oral contraception in diabetic women. A cross-over study on serum and high density lipoprotein (HDL) lipids and diabetes control during progestogen and combined estrogen/progestogen contraception. Hormone and metabolic research 1982;14:61-5.
3. Rogovskaya S, Rivera R, Grimes DA, Chen PL, Pierre-Louis B, Prilepskaya V, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstetrics and gynaecology 2005;105:811-5.
4. Skouby SO, Molsted-Pedersen L, Kuhl C, Bennet P. Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles. Fertility and sterility 1986;46:858-64.
5. Aznar R, Lara R, Zarco D, Gonzalez L. The effect of various contraceptive hormonal therapies in women with normal and diabetic oral glucose tolerance test. Contraception 1976;13:299-311.
6. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot Medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. The journal of obstetrics and gynaecology research 2000;26:17-26.
7. Klein BE, Klein R, Moss SE. Mortality and hormone-related exposures in women with diabetes. Diabetes care 1999;22:248-52.
8. Petersen KR, Skouby SO, Sidelmanm J, Molsted-Pedersen L, Jespersen J. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. American journal of obstetrics and gynecology 1994;171:400-5.
9. Petersen KR, Skouby SO, Vedel P, Haaber A. Hormonal contraception in women with IDDM. Influence on glycometabolic control and lipoprotein metabolism. Diabetes care 1995;18:800-6.
10. Petersen KR, Skouby SO, Jespen PV, Haaber AB. Diabetes regulation and oral contraceptives. Lipoprotein metabolism in women with insulin dependent diabetes mellitus using oral contraceptives [Diabetesregulering og p-pillen]. Ugeskrift for laeger 1996;158:2388-92.
11. Reder JA, Tulgan H. Impairment of diabetic control by norethynodrel with mestranol. New York state journal of medicine 1967;67:1073-4.
12. Skouby SO, Molsted-Pedersen L, Kuhl C. Contraception in diabetic women. Acta Endocrinologica. Supplementum 1986;277:125-9.
13. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Archives of internal medicine 1993;153:2209-16.
14. Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting results. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (updated May 2005);section 8. In The Cochrane Library, Issue 3,2005. Chichester, UK: John Wiley & Sons, LTD, 2005.
15. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med 1982;306:1332-7.
16. Elkind-Hirsch, Goldzieher JW. Carbohydrate metabolism. Pharmacology of the contraceptive steroids. New York, USA: Raven Press, 1994.
17. Erikson R, Goldthorpe JH, Portocarero L. Intergenerational class mobility and the convergence thesis: England, France, and Sweden. The British journal of sociology 1983;34:303-343.
18. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-4.
19. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991;34:356-61.
20. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. The journal of the American Medical Association 1994;271:1099-102.
21. Girling J, Dornhorst A. Pregnancy and diabetes mellitus. In: PickupJC, WilliamsG editor(s). Textbook of diabetes 2; section 65. Oxford, UK: Blackwell Science Ltd, 2003.
22. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. The New England journal of medicine 1990;323:1375-81.
23. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. The journal of clinical endocrinology and metabolism 1992;74:64-70.
24. Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. Journal of internal medicine 1996;738(supplement) :1-60.
25. Godsland IF, Winkler U, Lidegaard O, Crook D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs 2000;60:721-869.
26. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005;105:1114-8.
27. Heinenman MJ, Bleker OP, Evers JLH, Heintz APM, editors. Obstetrie en gynaecologie. De voortplanting van de mens; section 12. third. Maarssen, the Netherlands: Elsevier/ Bunge, 1999.
28. Kimmerle R, Schmitt G, Berger M. Contraception in patients with type I diabetes: a survey of 808 women of reproductive age. Geburtshilfe und Frauenheilkunde 1994;54:691-6.
29. Kjær K, Hagen C, Sandø SH, Eshøj O. Contraception in women with IDDM. An epidemicological study. Diabetes Care 1992;15:1585-90.
30. Klein BE, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes care 1999;22:1984-7.
31. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
32. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT, Prevention of Renal and Vascular End Stage Disease Study Group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Archives of internal medicine 2001;161:2000-5.
33. Napoli A, Colatrella A, Botta R, Di Cianni G, Fresa R, Gamba S, et al. Contraception in diabetic women: an Italian study. Diabetes Research and Clinical Practice 2005;67:267-72.
34. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456-8.
35. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614-8.
36. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002;359:696-700.
37. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359:781-5.
38. Simon D, Senan C, Garnier P, Saint-Paul M, Garet E, Thibult N, et al. Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: the Telecom study. American journal of obstetrics and gynecology 1990;163:382-7.
39. Steel JM. Diabetes mellitus in pregnancy. In: PickupJC, WilliamsG editor(s). Textbook of diabetes;section 60. second. Oxford, UK: Blackwell Science Ltd, 1997.
40. Vandenbroucke JP. When are observational studies as credible as randomised trials?. The Lancet 2004;363:1728-31.
41. Reproductive Health and Research. World Health Organzation. Medical eligibility criteria for contraceptive use. Geneva; Switserland: World Health Organization, 2004.
42. Wynn V, Adams PW, Godsland I, Melrose J, Niththyananthan R, Oakley NW, et al. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1979;1:1045-9.
43. Wynn V, Godsland I. Effects of oral contraceptives on carbohydrate metabolism. The Journal of reproductive medicine 1986;31:892-7.